1. Introduction {#sec1-nutrients-11-00397}
===============

Vitamin B~12~ deficiency (serum vitamin B~12~ \<148.0 pmol/L) is a major public health problem globally \[[@B1-nutrients-11-00397],[@B2-nutrients-11-00397]\]. Although the overall prevalence of vitamin B~12~ deficiency in the United States is estimated to be relatively low (6%), the burden of vitamin B~12~ deficiency is higher in the elderly, pregnant women, and young children (6--25%) \[[@B3-nutrients-11-00397]\]. Pregnant adolescents are at increased risk for a variety of micronutrient deficiencies and pregnancy complications, though there is limited data from this high-risk obstetric population.

Vitamin B~12~ deficiency in pregnancy has been associated with increased risk of pregnancy outcomes, including spontaneous abortion, pregnancy loss, intrauterine growth restriction, low birthweight (\<2500 g), and neural tube defects (NTDs) \[[@B4-nutrients-11-00397],[@B5-nutrients-11-00397],[@B6-nutrients-11-00397],[@B7-nutrients-11-00397],[@B8-nutrients-11-00397],[@B9-nutrients-11-00397],[@B10-nutrients-11-00397],[@B11-nutrients-11-00397],[@B12-nutrients-11-00397],[@B13-nutrients-11-00397],[@B14-nutrients-11-00397],[@B15-nutrients-11-00397]\]. Inadequate supply of vitamin B~12~ in pregnancy and early childhood can lead to long-term deficits in growth development in children \[[@B16-nutrients-11-00397],[@B17-nutrients-11-00397]\].

Maternal vitamin B~12~ concentrations during pregnancy are thought to predict fetal \[[@B18-nutrients-11-00397],[@B19-nutrients-11-00397],[@B20-nutrients-11-00397],[@B21-nutrients-11-00397],[@B22-nutrients-11-00397],[@B23-nutrients-11-00397],[@B24-nutrients-11-00397],[@B25-nutrients-11-00397],[@B26-nutrients-11-00397]\] and early infant \[[@B25-nutrients-11-00397],[@B27-nutrients-11-00397],[@B28-nutrients-11-00397],[@B29-nutrients-11-00397]\] vitamin B~12~ status. Previous cross-sectional studies in Norway, Turkey, Germany, United Kingdom, Serbia, and Brazil have noted a significant correlation between maternal and infant vitamin B~12~ status at delivery \[[@B18-nutrients-11-00397],[@B20-nutrients-11-00397],[@B21-nutrients-11-00397],[@B22-nutrients-11-00397],[@B30-nutrients-11-00397],[@B31-nutrients-11-00397],[@B32-nutrients-11-00397],[@B33-nutrients-11-00397]\]; however, in one study in Belgium, maternal and infant vitamin B~12~ concentrations were not significantly correlated \[[@B34-nutrients-11-00397]\]. In one study in Germany, maternal serum vitamin B~12~ and holotranscobalamin (holoTC) concentrations at delivery were significantly correlated with cord blood holoTC concentrations (*p* \< 0.05) \[[@B18-nutrients-11-00397]\]. In contrast, findings from cross-sectional studies examining the associations between maternal and infant vitamin B~12~ concentrations later in the postpartum period have been heterogeneous \[[@B35-nutrients-11-00397],[@B36-nutrients-11-00397],[@B37-nutrients-11-00397],[@B38-nutrients-11-00397],[@B39-nutrients-11-00397],[@B40-nutrients-11-00397]\]. Maternal vitamin B~12~ and holoTC concentrations were significantly correlated with infant vitamin B~12~ concentrations in the first month (i.e., 2--30 days) postpartum in a study in Turkey \[[@B38-nutrients-11-00397]\]. In analyses in mother--infant dyads in the first 6 months postpartum, maternal and infant vitamin B~12~ concentrations were significantly associated in Canada and Cambodia (i.e., 3--27 weeks) \[[@B37-nutrients-11-00397]\], but not in India (i.e., 1--6 months) \[[@B35-nutrients-11-00397]\].

Prospective studies to date in The Netherlands, Norway, Turkey, India, and Spain have reported significant associations \[[@B19-nutrients-11-00397],[@B23-nutrients-11-00397],[@B24-nutrients-11-00397],[@B26-nutrients-11-00397],[@B29-nutrients-11-00397]\] between maternal vitamin B~12~ status during pregnancy and infant vitamin B~12~ status in cord blood or serum. In a prospective study in India, maternal vitamin B~12~ status during pregnancy was associated with infant vitamin B~12~ concentrations at 6 weeks of age \[[@B28-nutrients-11-00397]\]. In contrast, a study in Norway was conducted to examine the associations between maternal vitamin B~12~ biomarkers during pregnancy and vitamin B~12~ status in infants at birth and 6 months of age; maternal vitamin B~12~ concentrations did not significantly predict cord blood or infant vitamin B~12~ status, although there were significant associations noted for other biomarkers (i.e., maternal holoTC, holohaptocorrin (holoHC), and methylmalonic acid (MMA)) \[[@B25-nutrients-11-00397]\]. Although some studies to date have been conducted to examine vitamin B~12~ status in pregnant adolescents \[[@B41-nutrients-11-00397],[@B42-nutrients-11-00397],[@B43-nutrients-11-00397]\], most studies investigating the associations between maternal and infant vitamin B~12~ status have been conducted among adult pregnant women (i.e., 18 to 40 years). Of these studies, three cross-sectional studies reported participants which included adolescents, with age ranges of 15 to 38 years \[[@B32-nutrients-11-00397]\], 16 to 40 years \[[@B38-nutrients-11-00397]\], and 17 to 43 years \[[@B27-nutrients-11-00397]\]. However, adolescents comprised a small proportion (\<15%) of the sample, and data presented were not stratified by age group, which constrained analysis and interpretation of findings for adolescents. There are limited prospective studies on the associations between maternal and infant vitamin B~12~ status conducted in high-risk obstetric groups such as adolescents.

Pregnant adolescents are at increased risk for a variety of micronutrient deficiencies and pregnancy complications \[[@B41-nutrients-11-00397],[@B44-nutrients-11-00397]\]. The inadequate dietary intake of key nutrients among adolescents in industrialized countries \[[@B45-nutrients-11-00397]\], coupled with increased nutritional requirements for growth and development, warrants concern for health outcomes among pregnant adolescents. However, few data exist on the extent of vitamin B~12~ deficiency or its implications for fetal and child health in this high-risk obstetric population, which comprises over 5% of the US population and 11% globally \[[@B46-nutrients-11-00397],[@B47-nutrients-11-00397]\]. Well-designed prospective studies are needed to elucidate the burden of vitamin B~12~ insufficiency in this key high-risk population and its implications for maternal and child health.

We, therefore, conducted a prospective observational analysis to: (1) determine the prevalence of vitamin B~12~ deficiency and insufficiency in pregnant adolescents and their infants; and (2) examine the associations of maternal and neonatal vitamin B~12~ status in healthy pregnant adolescents.

2. Materials and Methods {#sec2-nutrients-11-00397}
========================

2.1. Study Population {#sec2dot1-nutrients-11-00397}
---------------------

Participants included in this study were enrolled in one of two prospective cohort studies funded by the United States Department of Agriculture (USDA). One study examined maternal and fetal bone health among pregnant adolescents ("bone health study") and collected maternal blood samples at mid-gestation and delivery, and cord blood samples at delivery. The other study evaluated iron status and anemia through gestation in pregnant adolescents aged 13 to 18 years and their infants ("anemia study"), and collected maternal and cord blood samples only at delivery. Both studies were observational cohort studies and not clinical trials (and, thus, do not need to be registered, as per protocol for clinical trials). Pregnant adolescents were recruited between 2006 and 2012, from the Rochester Adolescent Maternity Program (RAMP) in Rochester, New York.

Adolescents were eligible to participate if their pregnancies were 12 to 30 weeks in gestation at the time of the adolescents' enrollment in prenatal care at RAMP, and if the adolescents were healthy and carrying a single fetus. Adolescents were excluded if they had any known medical complications, including diabetes, preeclampsia, gestational hypertension, eating disorders, gastrointestinal diseases, HIV infection, or any other diagnosed medical conditions. Data on maternal and neonatal iron status \[[@B48-nutrients-11-00397],[@B49-nutrients-11-00397]\] and on vitamin B~12~ transporters in placental tissue from this population \[[@B50-nutrients-11-00397]\] have been previously reported.

2.2. Ethics {#sec2dot2-nutrients-11-00397}
-----------

Written informed consent was obtained from all study participants. The research protocol and study procedures were approved by the Institutional Review Boards (IRB) at Cornell University and the University of Rochester. The IRB approval included laboratory analyses of micronutrients in maternal and infant cord blood samples, including vitamin B~12~ and folate concentrations.

2.3. Follow-Up Procedures {#sec2dot3-nutrients-11-00397}
-------------------------

Structured interviews were conducted to collect demographic information, including maternal age, educational level, socioeconomic status, and obstetric history at the baseline clinic visit. Detailed clinical, dietary (i.e., 24-h dietary recall), anthropometric, and biochemical data were collected at each visit. The participant recruitment and flow chart are presented in [Figure 1](#nutrients-11-00397-f001){ref-type="fig"}. Of 251 participants who delivered at RAMP, a total of 194 participants (*n* = 138 participants in the bone study, recruited at mid-gestation; *n* = 56 participants in the anemia study, recruited at delivery) had archived blood samples available for analysis ([Figure 1](#nutrients-11-00397-f001){ref-type="fig"}). All adolescents attending the Rochester Adolescent Maternity Program were prescribed a prenatal supplement as standard of care, which contained 27 mg iron, 12 μg vitamin B~12~, 1000 μg folic acid, and other micronutrients (i.e., 1200 μg vitamin A, 120 mg vitamin C, 10 μg vitamin D~3~, 22 mg vitamin E, 1.84 mg thiamin, 3 mg riboflavin, 20 mg niacin, 10 mg vitamin B~6~, 200 mg calcium, 25 mg zinc, and 2000 μg copper).

2.4. Laboratory Analyses {#sec2dot4-nutrients-11-00397}
------------------------

Non-fasting maternal venous blood samples (mid-gestation, delivery) and infant cord blood samples were allowed to clot at room temperature, separated by centrifugation, processed, and stored below −80 °C until analysis. A total of 124 maternal mid-gestation (26.4 ± 3.5 weeks), 131 maternal delivery (40.0 ± 1.3 weeks), and 89 infant cord blood samples were available for analysis.

Vitamin B~12~ concentrations were measured by electrochemiluminescence using the IMMULITE 2000 immunoassay system (Siemens Medical Solutions Diagnostics, Los Angeles, CA, USA). Three levels of controls (Bio-Rad) were used for serum vitamin B~12~, with inter-assay coefficients of variation (CV) of 4.2% for Level 1 and 4.8% for Level 3. Serum folate concentrations were measured using the IMMULITE 2000 immunoassay system. The Bio-Rad Liquichek Immunoassay Plus Control (High & Low) were used as controls, with intra-assay precision of 6.7% and inter-assay precision of 6.6%.

2.5. Definitions of Outcomes {#sec2dot5-nutrients-11-00397}
----------------------------

Conventional cutoffs were used to categorize variables where available; otherwise, medians of variables were defined based on their distributions in the population. Vitamin B~12~ deficiency and insufficiency were defined, following standard Centers for Disease Control and Prevention (CDC) definitions, as less than 148 pmol/L and less than 221.0 pmol/L, respectively \[[@B51-nutrients-11-00397]\]. Anemia was defined as hemoglobin \<11.0 g/dL during the first and third trimesters, \<10.5 g/dL during the second trimester, and \<11.0 g/dL at delivery; and anemia status was adjusted for race \[[@B52-nutrients-11-00397]\]. Folate deficiency was defined as \<6.8 nmol/L \[[@B51-nutrients-11-00397]\]. Maternal BMI was defined as the ratio of weight in kg to height in m^2^ (kg/m^2^), and categorized as \<18.5, 18.5 to \<25.0, 25.0 to \<30.0, and ≥30.0 kg/m^2^, in accordance with the CDC and World Health Organization (WHO) classifications \[[@B53-nutrients-11-00397]\]. Infant low birthweight was defined as \<2500 g. Infant ponderal index was calculated as the ratio of weight in g to length in cm^3^ (g/cm^3^ × 100).

2.6. Statistical Analyses {#sec2dot6-nutrients-11-00397}
-------------------------

Binomial and linear regression models were used to examine the associations of maternal vitamin B~12~ status at mid-gestation and delivery with infant vitamin B~12~ status at birth. Binomial regression models were used to obtain risk ratio (RR) estimates for dichotomous variables \[[@B54-nutrients-11-00397],[@B55-nutrients-11-00397],[@B56-nutrients-11-00397]\]. Non-normally distributed variables were natural logarithmically transformed to ensure normality before further analysis. We also examined the associations between maternal and infant folate status. The values in [Table 1](#nutrients-11-00397-t001){ref-type="table"} are presented as non-transformed values for interpretation purposes.

We explored potential nonlinearity of the relationships between covariates and outcomes nonparametrically, using stepwise restricted cubic splines \[[@B57-nutrients-11-00397],[@B58-nutrients-11-00397]\]. If nonlinear associations were not reported, they were not significant. The Rothman and Greenland approach was used to evaluate and adjust for confounding, in which all known or suspected risk factors for the outcome which lead to a \>10% change-in-estimate were included in the models \[[@B59-nutrients-11-00397]\]. Observations with missing data for covariates were retained in analyses using the missing indicator method \[[@B60-nutrients-11-00397]\]. Statistical analyses were conducted using SAS software, version 9.4 (SAS Institute, Inc., Cary, NC, USA).

3. Results {#sec3-nutrients-11-00397}
==========

3.1. Baseline Characteristics {#sec3dot1-nutrients-11-00397}
-----------------------------

The characteristics of participants in this study are presented in [Table 1](#nutrients-11-00397-t001){ref-type="table"}. Participants and their infants enrolled in the overall cohort studies and in the current study (i.e., with available serum vitamin B~12~ data) were similar in terms of baseline characteristics, including maternal age, socioeconomic characteristics, and nutritional status. A total of 194 participants had archived samples available for analysis; 138 of these participants were recruited at mid-gestation (bone health study), and 56 participants were recruited at delivery (anemia study) ([Figure 1](#nutrients-11-00397-f001){ref-type="fig"}). We also examined potential differences in demographic, socioeconomic, and nutritional factors between participants in the two cohort studies. These variables were identified *a priori* as potential confounders and were considered and adjusted for in all of the multivariate analyses. Vitamin B~12~ and folate concentrations were analyzed in maternal samples that were collected at mid-gestation (*n* = 124) and delivery (*n* = 131); and in infant cord blood samples (*n* = 89).

3.2. Maternal and Neonatal Vitamin B~12~ Status {#sec3dot2-nutrients-11-00397}
-----------------------------------------------

Maternal and neonatal vitamin B~12~ status are presented in [Table 2](#nutrients-11-00397-t002){ref-type="table"}. At the mid-gestation visit (*n* = 124; 26.4 ± 3.5 weeks gestation), 1.6% of women were vitamin B~12~ deficient (*n* = 2/124; \<148.0 pmol/L), and 22.6% were vitamin B~12~ insufficient (*n* = 28/124; \<221.0 pmol/L). Maternal serum vitamin B~12~ concentrations significantly decreased from mid-gestation to delivery (*n* = 61; 39.9 ± 1.0 weeks; mid-gestation: median = 358.9, interquartile range (IQR) = 233.9, 400.7 vs. delivery: median = 226.2, IQR = 185.2, 311.8; *p* \< 0.0001).

The prevalence of maternal vitamin B~12~ insufficiency at delivery (*n* = 70/131; 53.4%) was significantly higher than at mid-gestation (*n* = 28/124; 22.6%, *p* \< 0.05). The prevalence of vitamin B~12~ insufficiency was low in infants at birth: 0.0% were vitamin B~12~ deficient (\<148.0 pmol/L), and 2.3% were vitamin B~12~ insufficient (\<221.0 pmol/L). No mothers or infants were folate deficient (\<6.8 nmol/L) or insufficient (\<10.0 nmol/L) during this study.

The associations between maternal and infant serum vitamin B~12~ concentrations are presented in [Table 3](#nutrients-11-00397-t003){ref-type="table"}. Maternal vitamin B~12~ status at mid-gestation was not significantly associated with infant serum vitamin B~12~ concentrations (*p* \> 0.05).

At delivery, maternal serum vitamin B~12~ concentrations (*p* \< 0.001) and vitamin B~12~ deficiency (*p* \< 0.0001) were significantly associated with infant serum vitamin B~12~ concentrations in multivariate analyses, adjusting for gestational age at sample collection, maternal age, parity, smoking status, relationship status, reported prenatal supplement use, pre-pregnancy BMI, race, and intake of vitamin B~12~ and folate. Similarly, maternal vitamin B~12~ insufficiency at delivery was significantly associated with infant serum vitamin B~12~ concentrations (*p* \< 0.01) in multivariate analyses, adjusting for gestational age at sample collection, maternal age, parity, smoking status, relationship status, reported prenatal supplement use, pre-pregnancy BMI, race, and intake of vitamin B~12~ and folate. Maternal serum folate concentrations were not significantly associated with infant serum vitamin B~12~ concentrations (*p* \> 0.05).

The associations between maternal vitamin B~12~ and folate statuses and infant serum folate concentrations are presented in [Table 4](#nutrients-11-00397-t004){ref-type="table"}. Maternal serum folate concentrations at mid-gestation were not significantly associated with infant serum folate concentrations (*p* \> 0.05).

Maternal serum folate concentrations at delivery were significantly associated with infant serum folate concentrations (*p* \< 0.0001) in multivariate analyses, adjusting for gestational age at sample collection, maternal age, parity, smoking status, relationship status, prenatal supplement use, pre-pregnancy BMI, race, and intake of vitamin B~12~ and folate. Similarly, lower maternal serum folate concentrations (\<40.0 nmol/L) at delivery were associated with lower infant serum folate concentrations (*p* \< 0.0001) in multivariate analyses, adjusting for gestational age at sample collection, maternal age, parity, smoking status, relationship status, prenatal supplement use, pre-pregnancy BMI, race, and intake of vitamin B~12~ and folate.

4. Discussion {#sec4-nutrients-11-00397}
=============

In this prospective analysis among pregnant adolescents, maternal vitamin B~12~ concentrations significantly decreased during pregnancy and predicted neonatal vitamin B~12~ status. Although the prevalence of vitamin B~12~ deficiency (\<148.0 pmol/L; 1.6%) was low in adolescents during pregnancy, 22.6% of adolescents were vitamin B~12~ insufficient (\<221.0 pmol/L; 22.6%) at mid-gestation. Maternal serum vitamin B~12~ concentrations decreased significantly during pregnancy, and at delivery, 15.3% of mothers were vitamin B~12~ deficient and 53.4% were vitamin B~12~ insufficient ([Table 2](#nutrients-11-00397-t002){ref-type="table"}).

This is among the first studies conducted to date to examine the burden of vitamin B~12~ deficiency in pregnant adolescents and its association with neonatal vitamin B~12~ status in this high-risk obstetric population. The prevalence of vitamin B~12~ deficiency in this study was low (1.6% mid-gestation, 15.3% delivery) and similar to a previous study conducted in Spain among pregnant adolescents (vitamin B~12~ deficiency, T1: 8.3%) \[[@B42-nutrients-11-00397]\]. However, the prevalence of vitamin B~12~ deficiency noted in this study was lower than previous studies conducted in pregnant adolescents in Canada (median, T3: 158 pmol/L, IQR: 114, 207 pmol/L; vitamin B~12~ \<148.0 pmol/L: 43%) \[[@B43-nutrients-11-00397]\] and in Venezuela (vitamin B~12~ \<200.0 pg/mL (\<148.0 pmol/L), T1: 50.0%, T2: 58.8%, T3: 72.5%) \[[@B61-nutrients-11-00397]\]. Maternal vitamin B~12~ concentrations in our study were also higher than in a previous study in pregnant adolescents in the United Kingdom (geometric mean, Trimester 3 (T3): 177 pmol/L, 95% CI: 169, 185 pmol/L) \[[@B41-nutrients-11-00397]\].

The prevalence of vitamin B~12~ insufficiency (\<221.0 pmol/L), however, was high in this study at both mid-gestation (22.6%) and delivery (53.4%). Although all participants were prescribed prenatal vitamins containing vitamin B~12~ and folic acid, self-reported adherence to prenatal supplements was low. Additionally, while most participants reported dietary intake of vitamin B~12~ at or above the RDA for this group (i.e., median (IQR): 4.5 (2.6, 6.6) µg/day vs. RDA: 2.6 µg/day), approximately 25% of participants reported dietary intake below the RDA. In addition to low dietary intake of vitamin B~12~, vitamin B~12~ absorption could also be impaired by inadequate bioavailability, losses from processing and cooking animal-source foods, high dose folic acid, metabolic changes during pregnancy (e.g., hemodilution, fetal transfer), gastrointestinal symptoms, infections, and medications \[[@B4-nutrients-11-00397],[@B62-nutrients-11-00397]\]. For example, since vitamin B~12~ is bound to protein carriers in the food matrix, vitamin B~12~ bioavailability may vary by food source \[[@B62-nutrients-11-00397],[@B63-nutrients-11-00397]\].

The decline in maternal vitamin B~12~ concentrations during gestation in this study is also consistent with previous studies in adult pregnant women in Canada \[[@B64-nutrients-11-00397]\], Spain \[[@B26-nutrients-11-00397]\], Norway \[[@B25-nutrients-11-00397],[@B29-nutrients-11-00397]\], and India \[[@B28-nutrients-11-00397],[@B65-nutrients-11-00397]\], and in 12 of 13 longitudinal studies included in a systematic review of vitamin B~12~ status and birthweight in adult pregnant women \[[@B66-nutrients-11-00397]\]. The observed decrease in vitamin B~12~ concentrations throughout pregnancy could be due to hemodilution, increased protein synthesis, increased requirements for methyl donors during gestation, or a low intake or adherence to prenatal supplements to meet increased requirements \[[@B67-nutrients-11-00397]\]. However, there are limited data from pregnant adolescents, who have higher nutritional requirements for their own growth.

The prevalence of vitamin B~12~ deficiency and insufficiency in infants was low in this study (0--3%). Infant vitamin B~12~ concentrations were 2.5-fold higher than maternal vitamin B~12~ concentrations at delivery. These findings are consistent with previous studies in adult pregnant women, which have reported neonatal vitamin B~12~ concentrations 27% to 100% higher than maternal concentrations at delivery \[[@B18-nutrients-11-00397],[@B19-nutrients-11-00397],[@B21-nutrients-11-00397],[@B26-nutrients-11-00397],[@B30-nutrients-11-00397],[@B31-nutrients-11-00397],[@B33-nutrients-11-00397]\] and mid-gestation \[[@B23-nutrients-11-00397]\], although this has not been reported in all studies \[[@B22-nutrients-11-00397],[@B25-nutrients-11-00397],[@B28-nutrients-11-00397],[@B29-nutrients-11-00397]\]. Higher vitamin B~12~ concentrations in offspring indicate active transfer to the fetus, which may occur due to upregulation of placental B~12~ transporter proteins or other active transport mechanisms that have yet to be established.

In this study, maternal vitamin B~12~ status at delivery, but not at mid-gestation, was significantly associated with infant vitamin B~12~ status. Maternal vitamin B~12~ status at delivery has been associated with vitamin B~12~ status in offspring at birth in previous cross-sectional studies \[[@B18-nutrients-11-00397],[@B20-nutrients-11-00397],[@B21-nutrients-11-00397],[@B22-nutrients-11-00397],[@B30-nutrients-11-00397],[@B31-nutrients-11-00397],[@B32-nutrients-11-00397],[@B33-nutrients-11-00397]\]. There are, however, limited prospective data on maternal vitamin B~12~ status during pregnancy and its association with infant vitamin B~12~ status---particularly among adolescents---to compare findings. Evidence from studies in adult pregnant women have reported significant correlations between maternal vitamin B~12~ status during pregnancy and their infants \[[@B19-nutrients-11-00397],[@B23-nutrients-11-00397],[@B24-nutrients-11-00397],[@B26-nutrients-11-00397],[@B29-nutrients-11-00397]\]. Few prospective analyses to date have considered potential confounders of these associations in multivariate analyses \[[@B25-nutrients-11-00397],[@B28-nutrients-11-00397]\]. In a recent study in adult pregnant women (median age = 22, IQR = 20--24 years) in Southern India, maternal vitamin B~12~ status during each trimester was associated with infant vitamin B~12~ status at 6 weeks of age \[[@B28-nutrients-11-00397]\], even after adjusting for maternal vitamin B~12~ supplementation. Similarly, a study conducted among pregnant women (mean age = 29.9, SD = 4.4 years) in Norway found that maternal vitamin B~12~ levels did not significantly predict cord blood or infant vitamin B~12~ status, although other vitamin B~12~ biomarkers (i.e., maternal holoTC, holoHC, MMA) were associated \[[@B25-nutrients-11-00397]\].

This study has several limitations. Neonatal micronutrient status was assessed at a single time point from cord blood, precluding our ability to evaluate longer-term impacts on infant vitamin B~12~ status or functional outcomes. Longitudinal data on maternal vitamin B~12~ concentrations were available only from a subset of participants in the parent cohort studies, limiting our ability to examine changes in vitamin B~12~ concentrations during pregnancy. Although participants in both cohort studies had similar sociodemographic characteristics (e.g., maternal age, gestational age at initiation of prenatal care, adherence to prenatal vitamins, gestational age at delivery), participants enrolled at mid-gestation (bone study) were more likely to be participants in the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) program, current smokers, Caucasian, primiparous, and had higher self-reported dietary intake of vitamin B~12~ and folate, compared to participants who were recruited at delivery (anemia). All of these variables were identified *a priori* as potential confounders and were considered and adjusted for in multivariate analyses; however, there may be residual confounding due to additional factors that were not evaluated or adjusted for in these studies. Vitamin B~12~ concentrations assessed at mid-gestation may not reflect vitamin B~12~ status during the relevant etiologic period periconceptionally or for maternal--fetal transfer of cobalamin and subsequent infant status and perinatal outcomes \[[@B68-nutrients-11-00397]\]. Additionally, serum folate is a biomarker of short-term dietary intake and does not reflect longer-term or usual intake. Vitamin B~12~ and folate assessments were also based on a single biomarker (i.e., total serum vitamin B~12~ and serum folate concentrations). Inclusion of additional circulating (i.e., holo-transcobalamin) and functional (i.e., methylmalonic acid) biomarkers of vitamin B~12~ metabolism and erythrocyte folate concentrations would improve assessment and interpretation of findings in mother--infant dyads \[[@B4-nutrients-11-00397]\]. Additionally, while the low prevalence of vitamin B~12~ deficiency in this study is similar to previous research in pregnant adolescents in Canada and the United Kingdom, a study population of generally adequate vitamin B~12~ status limits the generalizability of results to other populations that may be at greater risk for vitamin B~12~ deficiency, particularly in resource-limited settings \[[@B41-nutrients-11-00397],[@B43-nutrients-11-00397]\]. Findings should also be interpreted in the context of a folate-replete population (i.e., among participants prescribed high-dose prenatal folic acid (1000 μg) and in a population exposed to folic acid fortification); this also limits the generalizability of findings to other settings. Finally, although findings from this study demonstrated an association of maternal and infant vitamin B~12~ status at delivery, the interpretation of these findings is not causal. Future prospective studies are needed to examine mechanisms of vitamin B~12~ transfer to the fetus and to determine the impact of vitamin B~12~ status on maternal and child health outcomes.

5. Conclusions {#sec5-nutrients-11-00397}
==============

In summary, in this cohort of healthy pregnant adolescents, maternal vitamin B~12~ concentrations significantly decreased during pregnancy and predicted infant vitamin B~12~ status. This is one of the first prospective studies to date to evaluate the burden of vitamin B~12~ insufficiency in pregnant adolescents and their infants, a population that is at high risk for both micronutrient deficiencies and pregnancy complications. Findings suggest that vitamin B~12~ deficiency is an important public health problem in this high-risk obstetric population. Future research is needed to increase vitamin B~12~ status and improve the health of adolescent mothers and their children.
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###### 

Characteristics of the study population.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables ^a^                                    Original Cohort\          Current Study\            Recruited at Mid-Gestation\   Recruited at Delivery (*n* = 56)
                                                   (*n* = 251)               (*n* = 194)               (*n* = 138)                   
  ------------------------------------------------ ------------------------- ------------------------- ----------------------------- ----------------------------------
  **Maternal**                                                                                                                       

  Age at enrollment, years                         17.3 (16.5, 18.1)         17.3 (16.5, 18.1)         17.3 (16.4, 18.1)             17.3 (16.6, 18.1)

  Age at delivery, years                           17.5 (16.7, 18.3)         17.6 (16.8, 18.4)         17.6 (16.7, 18.4)             17.4 (16.9, 18.2)

    \<16 years, % (*n*)                            12.0 (30)                 9.8 (19)                  9.4 (13)                      10.7 (6)

  Gestational age at delivery, weeks               39.9 (38.7, 40.7)         40 (39.0, 40.9)           40.0 (38.9, 40.9)             40.0 (39.2, 41.0)

    Pre-term (\<37 weeks), % (*n*)                 8.0 (20)                  7.8 (15)                  8.8 (12)                      5.4 (3)

  Parity ≥1, % (*n*)                               17.3 (43)                 15.1 (29)                 8.7 (12)                      30.9 (17)

  Smoking at enrollment, % (*n*)                                                                                                     

    Never a smoker                                 77.8 (189)                78.5 (150)                77.5 (107)                    81.1 (43)

    Past smoker                                    15.2 (37)                 14.4 (27)                 12.3 (17)                     18.9 (10)

    Current smoker                                 7.0 (17)                  7.3 (14)                  10.1 (14)                     0.0 (0)

  Relationship status ^b^, % (*n*)                 13.5 (33)                 10.5 (20)                 1.5 (2)                       34.0 (18)

  WIC ^c^ program participant                      60.9 (148)                63.2 (120)                80.0 (100)                    37.7 (20)

  Self-reported prenatal supplement use, % (*n*)                                                                                     

    ≥2 pills per week                              54.1 (131)                55.5 (106)                56.6 (77)                     52.7 (29)

  Dietary folate, µg/day                           617.2 (397.0, 948.9)      617.2 (400.8, 950.45)     692.7 (464.2, 1020.6)         415.3 (283.9, 624.7)

  Dietary vitamin B~12~, µg/day                    4.6 (2.7, 6.5)            4.6 (2.7, 6.6)            5.0 (3.7, 6.9)                2.8 (1.4, 5.2)

  Pre-pregnancy BMI, kg/m^2^                       23.5 (20.8, 28.0)         23.7 (20.8, 28.0)         23.3 (20.8, 28.1)             24.7 (20.8, 27.9)

    \<18.5 kg/m^2^, % (*n*)                        6.9 (17)                  7.3 (14)                  6.62 (9)                      9.1 (5)

    ≥18.5 to \<25 kg/m^2^, % (*n*)                 54.3 (133)                52.4 (100)                55.2 (75)                     45.5 (25)

    ≥25.0 to \<30 kg/m^2^, % (*n*)                 20.8 (51)                 21.5 (41)                 19.9 (27)                     25.5 (14)

    ≥30 kg/m^2^, % (*n*)                           18.0 (44)                 18.9 (36)                 18.4 (25)                     20.0 (11)

  Gestational weight gain (GWG), kg                15.9 (11.8, 20.5)         16.4 (11.8, 20.5)         15.5 (11.8, 20.5)             17.3 (12.3, 21.4)

    Inadequate ^d^ GWG, % (*n*)                    15.0 (36)                 13.9 (26)                 14.3 (19)                     13.0 (7)

    Within IOM range, % (*n*)                      22.9 (55)                 24.0 (45)                 26.3 (35)                     18.5 (10)

    Excessive GWG, % (*n*)                         62.1 (149)                62.0 (116)                59.0 (79)                     68.5 (37)

  Race, % (*n*)                                                                                                                      

    Caucasian                                      27.9 (70)                 29.4 (57)                 33.3 (36)                     19.6 (11)

    African American                               71.3 (179)                69.6 (135)                65.2 (90)                     80.4 (45)

    Native American                                0.8 (2)                   1.0 (2)                   1.5 (2)                       0.0 (0)

  Ethnicity, % (*n*)                                                                                                                 

    Hispanic                                       24.3 (61)                 26.3 (51)                 24.6 (34)                     30.4 (17)

  **Infant**                                                                                                                         

  Birthweight, g                                   3206.0 (2904.0, 3550.0)   3266.0 (2928.0, 3581.0)   3258.0 (2892.0, 3581.0)       3318.5 (3055.5, 3584.0)

  Birth length, cm                                 51.0 (49.0, 52.7)         51.3 (49.5, 52.9)         51.0 (49.5, 52.5)             52.0 (50.0, 53.5)

  Weight-for-length *z*-score \< −2, % (*n*)       27.0 (60)                 27.0 (47)                 27.3 (35)                     26.1 (12)

  Ponderal index, g/cm^3^ × 100                    2.4 (2.2, 2.7)            2.4 (2.3, 2.7)            2.4 (2.2, 2.7)                2.4 (2.3, 2.6)

  Male sex, % (*n*)                                52.8 (132)                51.0 (99)                 50.7 (70)                     51.8 (29)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Values are median interquartile range (IQR) and % (*n*); ^b^ Data presented are adolescents that report being in a relationship during pregnancy vs. single; ^c^ The Special Supplemental Nutrition Program for Women, Infants, and Children (WIC); ^d^ Gestational Weight Gain: categorized as inadequate or excessive, using Institute of Medicine (IOM) recommendations that vary based on pre-partum body mass index (BMI).
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###### 

Maternal and infant vitamin B~12~ and folate status.

                                Maternal               Infant                                                                                                             
  ----------------------------- ---------------------- ---------------------- ---------------------- ---------------------- ---------------------- ---------------------- ----------------------
  *n*                           124                    131                    75                     56                     89                     58                     31
  Serum vitamin B~12~, pmol/L   343.7 (237.8, 400.7)   216.2 (161.6, 297.8)   216.2 (173.4, 311.8)   211.2 (158.7, 267.0)   597.0 (471.6, 796.3)   569.4 (478.6, 844.3)   602.9 (406.6, 722.1)
    \<148.0 pmol/L              1.6 (2)                15.3 (20)              14.7 (11)              16.1 (9)               0.0 (0)                0.0 (0)                0.0 (0)
    ≥148 to \<221.0 pmol/L      21.0 (26)              38.2 (50)              37.3 (28)              39.3 (22)              2.3 (2)                0.0 (0)                6.5 (2)
    ≥221 pmol/L                 77.4 (96)              46.6 (61)              48.0 (36)              44.6 (25)              99.8 (87)              100.0 (58)             93.5 (29)
  *n*                           122                    130                    74                     56                     86                     55                     31
  Serum folate, nmol/L          39.3 (31.7, 50.5)      39.7 (31.8, 50.4)      42.8 (32.2, 51.4)      37.7 (28.8, 48.4)      66.7 (53.1, 85.5)      66.3 (52.1, 84.4)      67.7 (55.5, 98.4)
    ≤29.45^b^ nmol/L            19.7 (24)              20.0 (26)              13.5 (10)              28.6 (16)              2.3 (2)                3.6 (2)                0.0 (0)
    \>29.45, ≤35.79 nmol/L      20.5 (25)              16.9 (22)              18.9 (14)              14.3 (8)               2.3 (2)                3.6 (2)                0.0 (0)
    \>35.79, ≤43.94 nmol/L      19.7 (24)              20.0 (26)              17.6 (13)              23.2 (13)              4.7 (4)                5.5 (3)                3.2 (1)
    \>43.94, ≤52.66 nmol/L      19.7 (24)              22.3 (29)              29.7 (22)              12.5 (7)               14.0 (12)              12.7 (7)               16.1 (5)
    \>52.66 nmol/L              20.5 (25)              20.8 (27)              20.3 (15)              21.4 (12)              76.7 (66)              74.6 (41)              80.7 (25)

^a^ Values are median and interquartile range (IQR) and (%) *n*. ^b^ Note: No values of serum folate were \<6.8 nmol/L; the cut-offs presented for serum folate are quintiles based on the distribution of serum folate concentrations at mid-gestation.
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###### 

Associations between maternal vitamin B~12~ and folate status with infant serum vitamin B~12~ concentrations.

                                                                                   Univariate ^b^   Multivariate ^c^   Multivariate ^d^                             
  --------------------------------- ----------------------------------------- ---- ---------------- ------------------ ------------------ ---------- -------------- ----------
  Serum vitamin B~12~, ^a^ pmol/L   Mid-gestation                             54   0.29 (0.17)      0.09               0.28 (0.16)        0.08       0.31 (0.16)    0.06
                                    Delivery (All)                            64   0.85 (0.12)      \<0.0001           0.74 (0.12)        \<0.0001   0.77 (0.12)    \<0.001
                                      Delivery (Recruited at mid-gestation)   33   0.57 (0.20)      0.004              0.53 (0.18)        0.003      0.53 (0.16)    0.001
                                      Delivery (Recruited at delivery)        31   1.09 (0.13)      \<0.0001           0.97 (0.14)        \<0.0001   1.02 (0.12)    \<0.001
    \<148.0 pmol/L                  Mid-gestation                             54   n/a              n/a                n/a                n/a        n/a            n/a
                                    Delivery (All)                            64   −0.65 (0.16)     \<0.0001           −0.54 (0.14)       0.0002     −0.62 (0.15)   \<0.0001
                                      Delivery (Recruited at mid-gestation)   33   −0.63 (0.22)     0.004              −0.60 (0.19)       0.002      −0.56 (0.18)   0.002
                                      Delivery (Recruited at delivery)        31   −0.72 (0.22)     0.001              −0.59 (0.22)       0.008      −0.67 (0.21)   0.002
    \<221.0 pmol/L                  Mid-gestation                             54   −0.16 (0.15)     0.28               −0.18 (0.14)       0.20       −0.18 (0.14)   0.21
                                    Delivery (All)                            64   −0.42 (0.12)     0.0007             −0.30 (0.12)       0.01       −0.33 (0.12)   0.008
                                      Delivery (Recruited at mid-gestation)   33   −0.23 (0.17)     0.17               −0.19 (0.16)       0.22       −0.26 (0.15)   0.07
                                      Delivery (Recruited at delivery)        31   −0.61 (0.17)     0.0004             −0.44 (0.17)       0.01       −0.41 (0.19)   0.03
  Serum folate ^a^, nmol/L          Mid-gestation                             53   −0.24 (0.14)     0.09               −0.24 (0.14)       0.09       −0.28 (0.15)   0.06
                                    Delivery (All)                            64   0.12 (0.16)      0.47               0.07 (0.16)        0.68       0.09 (0.17)    0.61
                                      Delivery (Recruited at mid-gestation)   33   0.09 (0.22)      0.69               0.12 (0.23)        0.60       0.16 (0.26)    0.54
                                      Delivery (Recruited at delivery)        31   0.12 (0.25)      0.63               0.06 (0.23)        0.81       0.11 (0.22)    0.62
    \<40.0 nmol/L                   Mid-gestation                             53   0.10 (0.12)      0.40               0.11 (0.12)        0.37       0.14 (0.13)    0.28
                                    Delivery (All)                            64   −0.06 (0.13)     0.65               0.02 (0.13)        0.87       0.02 (0.13)    0.88
                                      Delivery (Recruited at mid-gestation)   33   −0.05 (0.17)     0.76               −0.08 (0.17)       0.64       0.04 (0.20)    0.86
                                      Delivery (Recruited at delivery)        31   −0.08 (0.21)     0.69               0.11 (0.18)        0.56       0.15 (0.17)    0.39

^a^ Statistical analyses: Linear regression models were used to examine associations between maternal vitamin B~12~ and folate status and infant serum vitamin B~12~ concentrations; vitamin B~12~ and folate concentrations were natural logarithmically transformed prior to analyses; ^b^ Adjusted for gestational age of sample collection; ^c^ Adjusted for gestational age of sample collection, maternal age at delivery, parity (≥1 vs. 0), ever smoked (yes vs. no), relationship status (single vs. married/in a relationship), self-reported prenatal supplement use (≥2 vs. \<2 pills/week), pre-pregnancy BMI, and race (African American vs. other); ^d^ Adjusted for gestational age of sample collection, maternal age at delivery, parity (≥1 vs. 0), ever smoked (yes vs. no), relationship status (single vs. married/in a relationship), self-reported prenatal supplement use (≥2 vs. \<2 pills/week), pre-pregnancy BMI, race (African American vs. other), intake of vitamin B~12~, and intake of folate.

nutrients-11-00397-t004_Table 4

###### 

Associations between maternal Vitamin B~12~ and folate status with infant serum folate concentrations.

                                                                                  Univariate ^b^   Multivariate ^c^   Multivariate ^d^                             
  -------------------------------- ----------------------------------------- ---- ---------------- ------------------ ------------------ ---------- -------------- ----------
  Serum vitamin B~12~,^a^ pmol/L   Mid-gestation                             51   −0.04 (0.16)     0.79               −0.19 (0.14)       0.17       −0.16 (0.13)   0.22
                                   Delivery (All)                            61   −0.02 (0.11)     0.88               −0.08 (0.11)       0.48       −0.08 (0.11)   0.45
                                     Delivery (Recruited at mid-gestation)   30   −0.20 (0.15)     0.18               −0.20 (0.13)       0.13       −0.22 (0.12)   0.07
                                     Delivery (Recruited at delivery)        31   0.14 (0.16)      0.37               0.04 (0.15)        0.78       0.06 (0.15)    0.67
    \<148.0 pmol/L                 Mid-gestation                             51   n/a              n/a                n/a                n/a        n/a            n/a
                                   Delivery (All)                            61   0.07 (0.13)      0.60               0.16 (0.12)        0.16       0.18 (0.12)    0.14
                                     Delivery (Recruited at mid-gestation)   30   0.26 (0.17)      0.13               0.26 (0.14)        0.07       0.38 (0.13)    0.005
                                     Delivery (Recruited at delivery)        31   −0.10 (0.18)     0.57               0.07 (0.17)        0.65       0.03 (0.17)    0.88
    \<221.0 pmol/L                 Mid-gestation                             51   −0.05 (0.14)     0.71               0.01 (0.13)        0.91       0.07 (0.12)    0.54
                                   Delivery (All)                            61   −0.01 (0.09)     0.90               0.05 (0.09)        0.58       0.07 (0.09)    0.47
                                     Delivery (Recruited at mid-gestation)   30   0.18 (0.12)      0.12               0.22 (0.11)        0.04       0.27 (0.10)    0.006
                                     Delivery (Recruited at delivery)        31   −0.19 (0.13)     0.15               −0.09 (0.12)       0.45       −0.12 (0.13)   0.37
  Serum folate ^a^, nmol/L         Mid-gestation                             50   0.27 (0.14)      0.06               0.05 (0.13)        0.69       0.003 (0.13)   0.98
                                   Delivery (All)                            61   0.54 (0.09)      \<0.0001           0.47 (0.10)        \<0.0001   0.50 (0.10)    \<0.0001
                                     Delivery (Recruited at mid-gestation)   30   0.54 (0.11)      \<0.0001           0.55 (0.13)        \<0.001    0.53 (0.15)    0.0003
                                     Delivery (Recruited at delivery)        31   0.57 (0.13)      \<0.0001           0.45 (0.13)        0.0005     0.44 (0.12)    0.0003
    \<40.0 nmol/L                  Mid-gestation                             50   −0.25 (0.12)     0.03               −0.13 (0.10)       0.21       −0.09 (0.10)   0.39
                                   Delivery (All)                            61   −0.42 (0.08)     \<0.0001           −0.40 (0.08)       \<0.0001   −0.42 (0.08)   \<0.0001
                                     Delivery (Recruited at mid-gestation)   30   −0.44 (0.09)     \<0.0001           −0.43 (0.10)       \<0.0001   −0.51 (0.12)   \<0.0001
                                     Delivery (Recruited at delivery)        31   −0.41 (0.12)     0.0006             −0.32 (0.12)       0.01       −0.33 (0.12)   0.006

^a^ Statistical analyses: linear regression models were used to examine associations between maternal vitamin B~12~ and folate status and infant serum vitamin B~12~ concentrations; vitamin B~12~ and folate concentrations were natural logarithmically transformed prior to analyses; ^b^ Adjusted for gestational age of sample collection; ^c^ Adjusted for gestational age of sample collection, maternal age at delivery, parity (≥1 vs. 0), ever smoked (yes vs. no), relationship status (single vs. married/in a relationship), self-reported prenatal supplement use (≥2 vs. \<2 pills/week), pre-pregnancy BMI, and race (African American vs. other); ^d^ Adjusted for gestational age of sample collection, maternal age at delivery, parity (≥1 vs. 0), ever smoked (yes vs. no), relationship status (single vs. married/in a relationship), self-reported prenatal supplement use (≥2 vs. \<2 pills/week), pre-pregnancy BMI, race (African American vs. other), intake of vitamin B~12~, and intake of folate
